Target intelligence / Profile preview

Inflammatory cytokines release

Molecular classification
Other (biological process)
01

Overview

"Inflammatory cytokines release" refers to the tightly regulated process by which immune cells, such as macrophages, neutrophils, and T cells, secrete small signaling proteins called cytokines into the extracellular environment in response to infection, tissue injury, or immune stimuli. Key cytokines include tumor necrosis factor, interleukins (e.g., IL-1, IL-6), and interferons. These cytokines mediate cell-cell communication to coordinate inflammation, recruit immune cells, and promote host defense. However, excessive or dysregulated cytokine release leads to pathological inflammation and tissue damage, as seen in cytokine release syndrome ("cytokine storm"), sepsis, and autoimmune diseases. Various molecular pathways, such as Toll-like receptor signaling, JAK-STAT, MAPK, and NF-κB, regulate cytokine gene expression and secretion, providing therapeutic targets for immune-mediated diseases[1][2][4][7].

Other names
Cytokine releaseCytokine secretionPro-inflammatory cytokine release
02

Mechanism of action

Inhibition of cytokine secretion (via neutralizing antibodies—e.g., anti-TNF, anti-IL-6); Inhibition of cytokine receptors (blocking downstream signaling); Modulation of transcription factors (e.g., NF-κB, STATs) -- which control cytokine gene expression; Inhibition of intracellular signaling pathways (e.g., JAK-STAT, MAPK)

03

Biological functions

Immune responseInflammationSignal transductionCell-cell communication
04

Disease associations

InflammationInfectionAutoimmune diseaseCytokine release syndrome (cytokine storm)Cancer
05

Safety considerations

Over-suppression of immune response, leading to infection riskRisk of immunopathology (cytokine storm, multiorgan dysfunction if not controlled)Difficulties with therapeutic specificity, since many cytokines have overlapping or compensatory effects
06

Interacting drugs

Anti-TNF antibodies (e.g., infliximab, adalimumab)

3 more in the full profile.

07

Biomarkers

Tumor necrosis factor (TNF)Interleukin-1β (IL-1β)Interleukin-6 (IL-6)Interferon-γ (IFN-γ)C-reactive protein (secondary acute phase reactant)

Beyond the preview

Go deeper on Inflammatory cytokines release.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflammatory cytokines release.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call